Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny

The FDA advisory panel will vote on Moderna's flu vaccine in older adults after regulators reversed an earlier rejection of the application. The decision is a modest positive for Moderna because it reopens a path toward approval, though the outcome remains uncertain. Any market impact is likely limited to Moderna shares and the vaccines segment rather than the broader market.

Analysis

The FDA advisory panel will vote on Moderna's flu vaccine in older adults after regulators reversed an earlier rejection of the application. The decision is a modest positive for Moderna because it reopens a path toward approval, though the outcome remains uncertain. Any market impact is likely limited to Moderna shares and the vaccines segment rather than the broader market.